Some studies have also shown that CD80-Fc can enhance T cell immune responses to a variety of tumor-associated antigens including Survivin and HPV, showing its potential as a universal adjuvant for tumor vaccines (86). This evidence concerns the gene BIRC5 and neoplasm.